Justin Sullivan/Getty Images News Gilead Sciences ( GILD ) has agreed to acquire biotechnology company Arcellx ( ACLX ) for $115 per share in cash at closing and one contingent value right (CVR) of $5 per share, which represents an implied equity value of $7.8B payable at closing. The transaction was approved by both the Gilead and Arcellx boards of directors and is anticipated to close during the...
Justin Sullivan/Getty Images News Gilead Sciences ( GILD ) has agreed to acquire biotechnology company Arcellx ( ACLX ) for $115 per share in cash at closing and one contingent value right (CVR) of $5 per share, which represents an implied equity value of $7.8B payable at closing. The transaction was approved by both the Gilead and Arcellx boards of directors and is anticipated to close during the second quarter of 2026. Arcellx is developing a new class of innovative immunotherapies for patients with cancer and other incurable diseases. Kite, a Gilead ( GILD ) company, and Arcellx have an existing collaboration to co-develop and co-commercialize Arcellx’s lead pipeline candidate, anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for patients with multiple myeloma. Shares of Arcellx ( ACLX ) jumped 77.7% premarket following the announcement. Under the merger agreement, a wholly owned Gilead subsidiary will launch a tender offer to buy all Arcellx shares it does not already own for $115 per share in cash, a 68% premium to Arcellx’s 30-day average price as of February 20, 2026. Gilead currently owns around 11.5% of Arcellx’s outstanding common stock. Shareholders will also receive one non-transferable CVR per share, which could pay an additional $5 if anito-cel achieves at least $6B in cumulative global net sales from launch through the end of 2029. If the tender offer is completed, Gilead will acquire any remaining Arcellx shares through a second-step merger on the same terms. Upon FDA approval of anito-cel, the proposed transaction is expected to be accretive to earnings per share in 2028 and thereafter. The BLA for anito-cel as a fourth-line treatment for patients with relapsed or refractory multiple myeloma is supported by results from the Phase 1 study (NCT04155749) and the pivotal Phase 2 iMMagine1 study (NCT05396885) and has been accepted by the U.S. Food and Drug Administration with an anticipated Prescription Drug User...
President Donald Trump’s decision to increase the level tariffs on U.S. imports, less than 24 hours after declaring his original schedule provided “great certainty” for the global economy, again has stoked concerns over trade policy and ignited another round of “Sell America” pressures in trading Monday. Trump, who said Friday he would use an untested section of the Trade Act of 1974 to impose a 1...
President Donald Trump’s decision to increase the level tariffs on U.S. imports, less than 24 hours after declaring his original schedule provided “great certainty” for the global economy, again has stoked concerns over trade policy and ignited another round of “Sell America” pressures in trading Monday. Trump, who said Friday he would use an untested section of the Trade Act of 1974 to impose a 10% tariff on goods from abroad after losing a Supreme Court ruling on his use of emergency powers, abruptly changed tack and increased the levy to 15% in a social media post published on Saturday. The move left many U.S. trade partners, some of which are in the process of ratifying deals made last year in the wake of the sweeping levies the Supreme Court now ruled illegal, in limbo or seeking to cut new deals with Washington based on the new tariff schedule.
Good morning . Markets react to Donald Trump’s plan for a 15% global rate. The US president is weighing a big strike on Iran if talks fail, the NYT reported. And a powerful storm is coming for New York City. Listen to the day’s top stories . S&P 500 Index Futures 6,907.25 -0.23% Nasdaq 100 Index Futures 24,975 -0.37% Bloomberg Dollar Spot Index 1,187.81 -0.07% Tariffs unknown: Donald Trump announc...
Good morning . Markets react to Donald Trump’s plan for a 15% global rate. The US president is weighing a big strike on Iran if talks fail, the NYT reported. And a powerful storm is coming for New York City. Listen to the day’s top stories . S&P 500 Index Futures 6,907.25 -0.23% Nasdaq 100 Index Futures 24,975 -0.37% Bloomberg Dollar Spot Index 1,187.81 -0.07% Tariffs unknown: Donald Trump announced a 15% global duty following the Supreme Court decision to void his previous tariffs. The president may lean on alternative legislation to try to rebuild his tariff wall, but senior US officials said the defeat won’t unravel previous deals negotiated , as they tried to defend the administration’s assertive trade policies. China, India and Brazil are the top winners from the court decision, according to Global Trade Alert, with New Delhi postponing a trip to the US aimed at finalizing their interim deal . The UK, meanwhile, risks being the biggest loser . The dollar and stock futures declined this morning as trade jitters hit market sentiment . Bitcoin also fell, briefly sliding below $65,000 for the second time this month, on tariff uncertainty. Other coins fared worse, with Ether—the second-largest cryptocurrency—retreating 5%. US-Iran Conflict May Push Oil to $75-90 Range FGE NexantECA Chairman Emeritus Fereidun Fesharaki believes an open conflict between the US and Iran could push prices into the $75-$90 per barrel range. Watch the Video Iran latest: Donald Trump said he’s considering limited military strikes on the Islamic Republic to pressure it into signing a new nuclear deal. If that effort fails, he’ll consider a bigger attack aimed at driving the country’s leaders from power, the New York Times reported. The two sides are set to resume talks in Geneva on Thursday. Meanwhile, protests have resurfaced at several Iranian universities for a second day. Across the border, Mexican authorities killed cartel leader Nemesio Rubén Oseguera Cervantes, known as “El Mencho,” ...
SoFi Technologies (NASDAQ: SOFI) is one of the most popular stocks in the financial sector right now, and for good reason. The business has been growing rapidly for years, with no signs of slowing down, and long-term investors have been handsomely rewarded. Even after a substantial pullback in recent months, SoFi has delivered a 180% return for investors over the past three years. Thanks to a new ...
SoFi Technologies (NASDAQ: SOFI) is one of the most popular stocks in the financial sector right now, and for good reason. The business has been growing rapidly for years, with no signs of slowing down, and long-term investors have been handsomely rewarded. Even after a substantial pullback in recent months, SoFi has delivered a 180% return for investors over the past three years. Thanks to a new ETF launched by Direxion, investors can now supercharge their exposure to SoFi. The Direxion Daily SoFi Bull 2X ETF (NASDAQ: SOFA) is designed to deliver twice the daily returns of SoFi stock -- so if SoFi gains 5% on a strong day, this ETF should gain 10%. As mentioned, there are plenty of good reasons to like SoFi as a long-term investment . Revenue grew 37% year-over-year in the most recent quarter, the bank is now highly profitable with a 17% net margin, and loan originations, new member additions, and general innovation within the business has never been higher. But it's important to know what you're getting into before you invest in a leveraged ETF like the Direxion Daily SoFi Bull 2X ETF. Continue reading
*Other Operating Data Consensus Source: Bloomberg More on Domino's Pizza Domino's Pizza: Lacks Clear Catalyst Through 2026 (Rating Downgrade) Domino's Missed The Value Rotation Domino's Pizza Is Now A Fresh Buy After The Recent Dip (Rating Upgrade) Domino's Pizza GAAP EPS of $5.35 misses by $0.04, revenue of $1.54B beats by $20M Domino's Pizza Q4 2025 Earnings Preview
*Other Operating Data Consensus Source: Bloomberg More on Domino's Pizza Domino's Pizza: Lacks Clear Catalyst Through 2026 (Rating Downgrade) Domino's Missed The Value Rotation Domino's Pizza Is Now A Fresh Buy After The Recent Dip (Rating Upgrade) Domino's Pizza GAAP EPS of $5.35 misses by $0.04, revenue of $1.54B beats by $20M Domino's Pizza Q4 2025 Earnings Preview
FinkAvenue/iStock Editorial via Getty Images Co-authored by Kody's Dividends Among dividend growth stocks, Dividend Aristocrats stand out more than nearly every other group of dividend stocks. That's because these S&P 500 index ( SP500 ) components have proven themselves. Raising payouts to shareholders for at least 25 consecutive years is a very difficult feat to achieve. The empirical evidence i...
FinkAvenue/iStock Editorial via Getty Images Co-authored by Kody's Dividends Among dividend growth stocks, Dividend Aristocrats stand out more than nearly every other group of dividend stocks. That's because these S&P 500 index ( SP500 ) components have proven themselves. Raising payouts to shareholders for at least 25 consecutive years is a very difficult feat to achieve. The empirical evidence is overwhelming. Out of thousands of dividend-paying stocks, only around 70 fulfill the requirements to qualify. Think about it. The past 25 years have included some turbulent times, including the Great Recession, the COVID-19 pandemic, and the highest inflation rate since the 1980s. Growing revenue and earnings in these environments serve as a litmus test for the quality of an underlying business. Rather than focusing on a current Dividend Aristocrat, however, we're focusing on what we believe is a Dividend Aristocrat in the making. We're referring to the payment processing giant, Visa Inc. ( V ). When Kody last covered it with a Buy rating in November , he liked that it beat analyst expectations in Q4 2025. The AA- S&P credit rating was another plus. The 13.6% boost in the quarterly dividend per share to $0.67 was another selling point. Clinching the buy case, shares were trading at a double-digit percentage discount to Kody's fair value estimate at the time. Two and a half months later, we're reiterating Kody's Buy rating. Visa is executing to sustain healthy adjusted diluted EPS growth in the coming years. The company's net debt-to-EBITDA ratio is tremendous. Finally, shares look even cheaper now than they were in November. Visa Continues To Execute Visa Q1 2026 Earnings Press Release On January 29th, Visa shared its financial results for the fiscal first quarter ended December 31st, 2025. The company's net revenue rose by 14.6% year-over-year to $10.90 billion. This was $210 million greater than Seeking Alpha's analyst consensus in the quarter. Put into context, that wa...